NCT04184050CompletedPhase 1
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Apr 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 9 Aug 2024
- Start date
- 26 Oct 2020
- Lead sponsor
- Harpoon Therapeutics Inc.
- Diseases
- Multiple myeloma
- NCT number
- NCT04184050
- EU CT number
- 2024-515582-33-00
- EudraCT number
- 2019-004793-26
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 10
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Catala d'oncologia Hospital Universitari Germans Trias i Pujol Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Hospital Universitario de Navarra Coordinator of this site? Confirm its status | Pamplona | Spain | Completed |
| Hospital Universitario De Salamanca Coordinator of this site? Confirm its status | Salamanca | Spain | Completed |
| CHU Nantes Coordinator of this site? Confirm its status | Nantes | France | Completed |
| Centre Hospitalier Universitaire de Poitiers Coordinator of this site? Confirm its status | Poitiers | France | Completed |
Related publications
- MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study.Lancet Haematol · 2026 · PMID 42838070
This page is information, not medical advice. Discuss any trial with your doctor.